Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial

BACKGROUND: Fluticasone furoate/vilanterol trifenatate (FF/VI) is an inhaled therapy for the treatment of asthma, with a prolonged duration of anti-inflammatory and bronchodilatory action. This study investigated the global metabolomic and lipidomic profile following treatment with FF/VI or placebo...

Descripción completa

Detalles Bibliográficos
Autores principales: Daley-Yates, Peter, Keppler, Brian, Baines, Amanda, Bardsley, George, Fingleton, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487108/
https://www.ncbi.nlm.nih.gov/pubmed/36127726
http://dx.doi.org/10.1186/s12931-022-02164-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487108/
https://www.ncbi.nlm.nih.gov/pubmed/36127726
http://dx.doi.org/10.1186/s12931-022-02164-w

Ejemplares similares